Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics: Cancer Growth and Progression, cartea 14
Editat de Jianguo Tao, Eduardo Sotomayoren Limba Engleză Paperback – 14 dec 2014
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 1070.12 lei 6-8 săpt. | |
SPRINGER NETHERLANDS – 14 dec 2014 | 1070.12 lei 6-8 săpt. | |
Hardback (1) | 1078.44 lei 6-8 săpt. | |
SPRINGER NETHERLANDS – 13 noi 2012 | 1078.44 lei 6-8 săpt. |
Din seria Cancer Growth and Progression
- 5% Preț: 1086.48 lei
- 14% Preț: 148.11 lei
- 5% Preț: 352.83 lei
- 5% Preț: 365.36 lei
- 5% Preț: 1006.71 lei
- 5% Preț: 1312.22 lei
- 5% Preț: 1341.60 lei
- 5% Preț: 1359.79 lei
- 5% Preț: 1072.26 lei
- 5% Preț: 1320.01 lei
- 5% Preț: 1382.16 lei
- 5% Preț: 1378.43 lei
- 5% Preț: 359.84 lei
- 5% Preț: 1378.27 lei
- 5% Preț: 356.66 lei
- 5% Preț: 713.35 lei
- 5% Preț: 1373.82 lei
Preț: 1070.12 lei
Preț vechi: 1126.44 lei
-5% Nou
Puncte Express: 1605
Preț estimativ în valută:
204.79€ • 214.76$ • 170.76£
204.79€ • 214.76$ • 170.76£
Carte tipărită la comandă
Livrare economică 08-22 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9789400795815
ISBN-10: 9400795815
Pagini: 432
Ilustrații: VI, 426 p.
Dimensiuni: 155 x 235 x 23 mm
Greutate: 0.6 kg
Ediția:2012
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Cancer Growth and Progression
Locul publicării:Dordrecht, Netherlands
ISBN-10: 9400795815
Pagini: 432
Ilustrații: VI, 426 p.
Dimensiuni: 155 x 235 x 23 mm
Greutate: 0.6 kg
Ediția:2012
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Cancer Growth and Progression
Locul publicării:Dordrecht, Netherlands
Public țintă
ResearchCuprins
Preface.-1 B-Cell Growth, Differentiation and Malignancies .-2 Follicular Lymphoma: Recent advances.-3 Chronic Lymphocytic Leukemia: From Pathobiology to Targeted Therapy.-4 Genetic and Environmental Determinants in Multiple Myeloma: Implications for Therapy.-5 EBV-Positive Diffuse Large B-Cell Lymphoma of the Elderly.-6 HIV and Lymphoma.-7 Molecular Biology of Mantle Cell Lymphoma.-8 Pathogenesis of Non-Hodgkin Lymphoma Derived from Inflammatory, Autoimmune or Immunologic Disorders.-9 Pathogenesis of Non-Hodgkin Lymphoma Derived from Infection Diseases.-10 Hodgkin Lymphoma: From Molecular Pathogenesis to Targeted Therapy.-11 Myelodysplastic Syndromes.-12 Chronic Myeloproliferative Disorders: from Molecular Pathogenesis to Targeted Therapy.-13 Chronic Myeloid Leukemia.-14 Novel Targeted Therapeutics for Acute Myeloid Leukemia.-15 Novel Targeted Therapeutics for Peripheral T-Cell Lymphoma.-16 Large Granular Lymphocyte Leukemia – From Molecular Pathogenesis to Targeted Therapy.-17 Epigenetic Regulation and Therapy in Lymphoid Malignancies.-Index.
Textul de pe ultima copertă
In the last decade, there has been a remarkable explosion of knowledge in hematologic cancer from basic molecular biology and pathology to clinical therapy. This has led to many new advance and insights in the understanding of pathobiology of malignant hematology. New knowledge of disease molecular pathology, cytogenetic, epigenetic and genomic alterations have provided new strategies to attack and eradicate tumor cells at molecular level and significantly impacted our current therapeutics for hematological malignancies. The recent and ongoing rapid expansion of knowledge in this area has become extensive, dynamic and diffuse over the literature and research publications. This has led to the need to capture and compile the new and current information about hematologic cancer with special emphasis on translation from molecular pathobiology to targeted therapeutics. In this book experts from around the world share their thoughts and knowledge about the pathobiology of hematologic cancer,as well as their view on current treatment approaches and future development in these malignant hematologic diseases. This book is well suited for hematology residents, fellows and hematology-oncology physicians, hematopathologist as well as basic research scientist in the area of hematologic malignancies.
Caracteristici
Compiles new knowledge on pathobiology of hematologic cancer Gives comprehensive information on current treatments on malignant hematologic diseases Written by international leaders on the field